# Targeting ferroptosis in renal tubular epithelial cells to improve outcomes of lupus nephritis > **NIH NIH R01** · UNIVERSITY OF FLORIDA · 2024 · $447,463 ## Abstract PROJECT SUMMARY/ABSTRACT Lupus nephritis is one of the most severe end-organ manifestations of systemic lupus erythematosus. Immunosuppression, the cornerstone for treating this disease, is complicated by many adverse effects. Although traditionally considered as a glomerular disease, up to 80% of lupus nephritis patients present with tubular injury, and tubular injury is a better predictor of progression to end stage kidney disease than glomerular injury. This identifies the renal tubules as a therapeutic target in lupus nephritis. The complex biological mechanisms that underlie tubular epithelial cell injury in lupus nephritis remain, for the most part, obscure. We propose to provide such a mechanistic understanding by leveraging our key novel findings. We have shown that iron accumulates in the tubular compartment of the lupus nephritis kidneys but not in the glomeruli. Most of the iron recycling in the kidney is performed by proximal tubular epithelial cells, and excess iron induces ferroptosis -- an inflammatory form of cell death characterized by high levels of lipid peroxidation. Ferroptosis is mostly observed in the tubular segments of human and murine lupus nephritis kidneys. We have found that the enzyme Acyl-CoA synthetase long-chain family member 4 (ACSL4), a ferroptosis promoter, was increased whereas SLC7A11, a ferroptosis inhibitor, was decreased in lupus nephritis. Additionally, human lupus nephritis serum induced ferroptosis in proximal tubular epithelial cells and this was associated with inflammation and injury. Liproxstain-2, a novel ferroptosis inhibitor, blocked these outcomes. These data led us to hypothesize that iron accumulation in proximal tubular epithelial cells promotes ferroptosis, propagates tubulointerstitial inflammation and worsens outcomes of lupus nephritis. We aim to test this hypothesis using congenic mice deficient for ACSL4 (Acsl4PTEC-/-) and SCL7A11 (Slc7a11PTEC-/-) only in their proximal tubular epithelial cells (PTEC). We will first investigate the resistance of Acsl4PTEC-/- and susceptibility of Slc7a11PTEC-/- mice to ferroptosis using an inducible and a spontaneous mouse model of immune complex glomerulonephritis, identify the downstream molecular pathways that block or lead to ferroptosis and follow the outcomes of kidney injury. Using lupus nephritis patients and healthy controls, we will dissect the ferroptosis inducing ability of whole and immunoglobin depleted serum on proximal tubular epithelial cells as well as test novel ACSL4 inhibitors. Using purified cells from the same cohort of patients and controls we will block known repressors of SLC7A11 and evaluate outcomes of ferroptosis and tubular pathology. Finally, we will evaluate the in vivo therapeutic efficacy of Liproxstain-2 in two spontaneous murine models of lupus nephritis with existing renal injury. These studies will identify novel mechanisms of proximal tubular epithelial cell injury in lupus nephritis and support use of ferroptos... ## Key facts - **NIH application ID:** 10817055 - **Project number:** 5R01DK136011-02 - **Recipient organization:** UNIVERSITY OF FLORIDA - **Principal Investigator:** Laurence Morel - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2024 - **Award amount:** $447,463 - **Award type:** 5 - **Project period:** 2023-04-01 → 2028-01-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10817055 ## Citation > US National Institutes of Health, RePORTER application 10817055, Targeting ferroptosis in renal tubular epithelial cells to improve outcomes of lupus nephritis (5R01DK136011-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10817055. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*